Cancer does not begin on the day it is diagnosed. Long before a tumor appears on a scan, cells may accumulate mutations and alter surrounding tissue. Pancreatic cancer, for example, can take a decade or more to develop from its earliest genetic changes.
For most of oncology’s history, this interval was difficult to see or to act on. Advances in genetics, early detection, immune monitoring, and precancer mapping are bringing it into view.
Consider heart disease: we manage high blood pressure and cholesterol years before a heart attack. Cancer offers a similar window. Together, new technologies, deeper biological understanding, and early clinical evidence point toward a future in which people can better understand their risk, work with their doctors to monitor meaningful changes, and intervene earlier.
Three Windows to Act
Efforts to prevent cancer from developing or returning fall into three windows.
Primary prevention acts before precancer develops by reducing cancer-causing exposures or infections, or potentially preparing immunity before dangerous changes appear.
Cancer interception acts after the earliest dangerous changes appear but before invasive cancer takes hold. Its goal is to eliminate abnormal cells or stop their progression.
Preventing recurrence acts after successful treatment and aims to eliminate residual cells before the disease returns.
Across these windows, abnormal cells may be absent, limited, or microscopic, while the immune system may still have an advantage. Acting earlier can mean fewer cells and barriers to overcome, but early changes can be difficult to recognize and may already suppress immunity.
Proof of Principle
For cancers caused by viruses, immune prevention is already a reality. Vaccines against hepatitis B virus and human papillomavirus (HPV) prevent infections that cause liver, cervical, and other cancers. Programs supported by Gavi, the Vaccine Alliance, have protected an estimated 86 million girls in lower-income countries, an effort projected to avert 1.4 million cervical cancer deaths. One-dose HPV vaccination reaching 80 percent coverage worldwide could prevent more than 50 million cervical cancer cases over the next century.
CRI helped advance this science. Beginning in 1999, CRI supported Ian H. Frazer, MD, whose pioneering work on virus-like particles contributed to the technology behind Gardasil®, an HPV vaccine.
Removing precancerous polyps during colonoscopy lowers cancer incidence and mortality. Daily aspirin reduces colorectal cancer in people with Lynch syndrome, and removing the ovaries and fallopian tubes reduces ovarian cancer risk in women who carry BRCA mutations.
The principle is established: intervening before invasive cancer emerges can save lives. The frontier is extending that principle to nonviral cancers by training the immune system to recognize and eliminate precancerous cells or residual cancer cells.
Promising Signals, Hard Lessons
Early trials show both the promise and difficulty of cancer interception.
A vaccine targeting MUC1, a protein altered on precancerous colon growths, produced an immune response in only one in four recipients and did not significantly reduce recurrence overall. Among those with a lasting response, however, recurrence was 38 percentage points lower than with placebo. Nonresponders already had more immune-suppressing cells and inflammatory signals before vaccination. This suggests that success may depend on both the right target and an immune system ready to respond. Understanding that baseline immune state could help determine whom to treat and whether immune suppression must first be addressed.
In another trial, nivolumab, an approved immunotherapy, shrank high-risk mouth lesions in about one in three participants. Yet some responders still developed invasive cancer, and one in five experienced severe immune-related side effects. The lesson is important: shrinking a lesion is not the same as preventing cancer. For someone who does not yet have cancer, a successful intervention must reduce future risk while protecting present health and quality of life.
Clear early targets offer another path. More than 90 percent of the most common form of pancreatic cancer and many of its precancerous lesions carry a mutation in a gene called KRAS. A vaccine against six common KRAS mutations produced an immune response in 90 percent of 20 high-risk participants, with vaccine-induced immune cells detectable for up to two years.
The study did not test prevention, but it answered two questions that had to come first: the vaccine could be given safely and generate a lasting immune response. A second group scheduled for surgery will help answer the next question: Do those immune cells reach the precancerous lesion, where they must act?
Lynch syndrome, which leaves people at high risk for colorectal and several other cancers, offers a similar strategy. This inherited condition disrupts the cell’s proofreading system, repeatedly producing some of the same mutations and creating shared vaccine targets. A vaccine targeting 209 of them generated an immune response in every participant. Whether those responses prevent cancer is the next test.
Together, these studies show that durable, targeted immune responses in people at elevated risk are possible. Turning those responses into prevention is the work ahead.
What it Will Take
Several connected challenges define the field.
- Knowing whom to treat, and when. Lifetime risk does not reveal whether cancer will develop soon, decades later, or at all. Risk assessment must combine genetics, exposures, imaging, and molecular biomarkers.
- Understanding early biology. Researchers must learn why some precancers progress while others remain stable or disappear, and which changes could serve as treatment targets.
- Building better models. Most cancer research studies tumors that are already established. Interception needs laboratory models in which cancer develops slowly, in its natural tissue, alongside a working immune system, and that are validated against human precancer.
- Measuring success. An immune response does not prove prevention. Reliable shorter-term markers are needed to avoid trials involving thousands of participants followed for years.
- Meeting a higher safety bar. Because many people treated may never develop cancer, interception must reduce future risk without compromising present health.
These challenges are inseparable. A target matters only if it appears early enough; a laboratory model only if it reflects human precancer; a biomarker only if it guides intervention or shows that it worked. Progress depends on linking these pieces from mechanistic discovery through clinical application.
Progress is already visible in the recurrence window. In August 2026, Merck and Moderna announced that a personalized mRNA vaccine, tailored to each person’s tumor mutations, plus pembrolizumab reduced the risk of melanoma returning after surgery in a large phase III trial. Full results are not published yet, but the finding supports immune-based prevention when any remaining disease is microscopic.
The Opportunity Ahead
CRI believes cancer interception could reshape cancer care, shifting more of it from treating established disease to preventing cancer from taking hold or returning. Realizing that vision requires team science linking fundamental immunology and cancer biology with early detection and rigorous clinical trials. CRI is committed to investing in the scientists, collaborations, and translational research needed to turn early promise into interventions that save lives.
The window before cancer is real. With rigorous science and sustained commitment, we can learn to use it to stop more cancers before people ever have to face them, or face them again.
